Independent editorial coverage · not a pharmacy

Policy

Policy & Regulation

How different regulators — the FDA, EMA, and NMPA — approve, classify, and oversee GLP-1 medications, and what that means for prescribing and access.

A hand holding an insurance card, face not shown
ExplainerOctober 29, 2026

The Medicare GLP-1 Bridge, Explained: Who Qualifies for the $50 Copay and How Long It Runs

Since July 1, 2026, a CMS demonstration has offered certain Part D enrollees Wegovy, Zepbound KwikPen, and Foundayo for weight management at a $50 monthly copay. CMS has extended it through December 31, 2027.

4 min read
Two identical vials side by side under laboratory lighting
ExplainerOctober 23, 2026

How Generic GLP-1 Drugs Get Approved: The ANDA Pathway for Peptides

Generic liraglutide reached U.S. pharmacies through the abbreviated generic-drug pathway, not the biosimilar route. In July 2026 the FDA revised its draft recommendations for generic semaglutide and tirzepatide as well.

4 min read
Sealed boxes on a customs inspection table in a warehouse
ExplainerOctober 19, 2026

The FDA's GLP-1 Ingredient 'Green List': How Import Alert 66-80 Works

Since September 2025, imported GLP-1 active ingredients can be detained at the U.S. border unless their manufacturer appears on an FDA green list, the reverse of the red-list approach many import alerts use.

4 min read
Close-up photo of ornate European civic building facades against a pale sky
SwitzerlandOctober 16, 2026

Switzerland: Swissmedic Approval and Specialty List Rules for GLP-1 Weight-Management Drugs

Swissmedic has approved Wegovy and Mounjaro for weight management, but basic health insurance pays only under strict, time-limited Specialty List conditions set by the Federal Office of Public Health.

4 min read
An open insurance benefits booklet on a desk
SingaporeOctober 12, 2026

Singapore: HSA Approval and Medication Assistance Fund Rules for GLP-1 Drugs

Singapore's Health Sciences Authority has expanded labelled uses for Wegovy and Ozempic through 2025, while ACE guidance still keeps semaglutide off the Medication Assistance Fund for type 2 diabetes.

4 min read
A calculator and prescription bottle on a desk
New ZealandOctober 9, 2026

New Zealand: Medsafe Approval and Pharmac Funding Decisions for GLP-1 Drugs

Medsafe has approved Wegovy and Mounjaro for weight management in New Zealand, but approval and public funding are separate decisions, and Pharmac has not funded either for weight loss.

4 min read
A law book with a bookmark on a desk
ExplainerJuly 8, 2026

How the FDA's Compounding Exemption Law Actually Works

Federal law allows pharmacy compounding under specific exemptions from standard drug approval requirements. Here's the legal structure behind that exemption.

6 min read
A laptop screen showing an abstract outline map of the United States
ExplainerJune 25, 2026

State-by-State Telehealth Prescribing Rules for GLP-1 Drugs

Telemedicine practice standards are set at the state level in the U.S., which means the rules governing a GLP-1 telehealth prescription can change at a state line.

6 min read
Exterior of a Canadian government building
CanadaJune 18, 2026

Canada: Health Canada Approval and Provincial Coverage Differences

Health Canada approves GLP-1 drugs nationally, but public drug coverage is administered provincially, creating access differences similar to the EU's member-state model.

5 min read
Close-up of the Houses of Parliament exterior in London
United KingdomJune 2, 2026

United Kingdom: MHRA Approval and NHS Access Rules

Post-Brexit, the UK's MHRA runs its own approval process separate from the EMA, and NHS access to GLP-1 drugs runs through NICE cost-effectiveness review.

6 min read
Close-up photo of the U.S. Capitol dome exterior
United StatesMay 20, 2026

United States: FDA Approval Pathway and Prescribing Rules for GLP-1 Drugs

How GLP-1 medications move through FDA approval, what prescription-only status means in practice, and where telehealth prescribing fits in.

6 min read
A prescription pad with a pen
ExplainerMay 15, 2026

Off-Label Prescribing: What's Legal, and What Insurance Won't Touch

Off-label prescribing is legal in the U.S. and common in medicine generally. Here's the legal basis for it, and why it doesn't guarantee insurance coverage.

5 min read
Close-up photo of ornate European civic building facades against a pale sky
European UnionMay 10, 2026

European Union: EMA Approval and Member-State Access Differences

The EMA approves GLP-1 drugs at the EU level, but pricing, reimbursement, and day-to-day access still vary significantly by member state.

5 min read
Photo of a government building facade, illustrative rendering — not an official photograph of NMPA headquarters
ChinaApril 28, 2026

China: NMPA Approval Status and the Domestic GLP-1 Market

China's National Medical Products Administration has approved semaglutide for diabetes and, more recently, weight management, alongside a growing field of domestic GLP-1 candidates.

6 min read
Glow of a television screen in a dim living room
ExplainerApril 10, 2026

Direct-to-Consumer Drug Advertising Rules and GLP-1 Marketing

The U.S. is one of the only countries that allows direct-to-consumer prescription drug advertising, and GLP-1 drugs have become some of its most visible examples.

5 min read
Close-up of a pen signing a document
ExplainerMarch 28, 2026

Medicare Part D Negotiation and GLP-1 Drugs, Explained

Medicare's drug price negotiation authority is new, statutorily limited, and doesn't automatically apply to every high-profile drug. Here's the actual legal structure.

5 min read
Exterior of an Australian government building
AustraliaMarch 14, 2026

Australia: TGA Approval and PBS Subsidy Rules

Australia's Therapeutic Goods Administration approves GLP-1 drugs, but Pharmaceutical Benefits Scheme subsidy is a separate, additional decision that determines affordability.

5 min read
Insurance policy documents fanned out on a table
ExplainerMarch 10, 2026

State Insurance Mandates for Obesity Treatment Coverage

A small number of U.S. states have passed laws requiring certain insurance plans to cover obesity treatment, including GLP-1 drugs. Here's how those mandates work.

6 min read
Exterior of a Japanese government building
JapanFebruary 25, 2026

Japan: PMDA Approval and National Health Insurance Coverage

Japan's Pharmaceuticals and Medical Devices Agency reviews GLP-1 drugs under its own process, with coverage tied to the country's universal National Health Insurance system.

5 min read
A pharmacy shelf, different angle
ExplainerFebruary 20, 2026

How the FDA Actually Declares and Resolves a Drug Shortage

A drug shortage designation follows a specific legal and evidentiary process, not a simple observation that a pharmacy is out of stock.

5 min read
Exterior of an Indian government building
IndiaFebruary 8, 2026

India: CDSCO Status and the Domestic Generics Question

India's patent and regulatory landscape has made it an early test case for lower-cost GLP-1 competition, subject to its own approval and patent rules.

6 min read
Exterior of a Brazilian government building
BrazilJanuary 22, 2026

Brazil: ANVISA Approval and Public Health System Access

Brazil's ANVISA regulates GLP-1 drugs nationally, with access shaped by both the public SUS health system and a large private insurance market.

5 min read
A rubber stamp and ink pad resting on a form
ExplainerJanuary 5, 2026

Prior Authorization: How Insurers Gatekeep GLP-1 Coverage

Prior authorization is the main tool insurers use to manage GLP-1 drug costs. Here's how the process typically works and what commonly triggers a denial.

6 min read
Exterior of a South Korean government building
South KoreaDecember 30, 2025

South Korea: MFDS Approval Status for GLP-1 Drugs

South Korea's Ministry of Food and Drug Safety reviews GLP-1 drugs under its own national process, alongside a growing domestic biopharmaceutical sector.

4 min read
A pharmacist's mortar and pestle on a counter
ExplainerDecember 22, 2025

Pharmacy Compounding Oversight: State Boards vs. Federal FDA Roles

Compounding pharmacies are regulated by both state pharmacy boards and the FDA, with overlapping but distinct authority. Here's how the split works.

6 min read
Exterior of a Mexican government building
MexicoDecember 12, 2025

Mexico: COFEPRIS Approval and Cross-Border Purchasing Questions

Mexico's COFEPRIS regulates GLP-1 drugs domestically, and the country has become a common topic in discussions of cross-border purchasing by U.S. patients.

5 min read
A customs declaration form and passport on a desk
ExplainerNovember 15, 2025

Customs and Personal-Import Rules for Prescription Drugs

Bringing prescription drugs into the U.S. from abroad, including GLP-1 drugs, is subject to specific and often misunderstood federal rules.

5 min read
Two identical vials side by side under laboratory lighting
ExplainerOctober 25, 2025

Biosimilar vs. Generic: Which Approval Pathway Applies to GLP-1 Drugs, Explained

Semaglutide and tirzepatide are peptides of 40 or fewer amino acids, so in the U.S. they are approved as drugs, and copies go through the generic (ANDA) pathway rather than the biosimilar route used for insulin. Here's the difference.

6 min read
A magnifying glass held over a blister pack of pills
ExplainerSeptember 28, 2025

The FDA's Legal Powers to Combat Counterfeit Drugs

The FDA has specific statutory tools for counterfeit drug enforcement, working alongside customs authorities and, in serious cases, criminal law enforcement.

5 min read
A clipboard with a checklist and a pen
ExplainerSeptember 10, 2025

What Companies Are Legally Required to Disclose About GLP-1 Clinical Trials

U.S. law requires registration and results reporting for many clinical trials on ClinicalTrials.gov. Here's what that requirement actually covers.

5 min read
Close-up of a patent certificate document, text blurred
ExplainerAugust 25, 2025

Patent and Regulatory Exclusivity Periods for GLP-1 Drugs, Explained

Patents and FDA regulatory exclusivity are two separate legal protections that both affect when competition can enter the GLP-1 market.

6 min read
Shipping containers and cargo pallets at a freight yard
ExplainerAugust 8, 2025

State Drug Importation Programs: How They Actually Work

Several states have pursued federally authorized programs to import lower-cost drugs from Canada. Here's the legal mechanism behind those efforts.

5 min read
An empty office wellness room with exercise equipment
ExplainerJuly 25, 2025

Employer Wellness Program Rules and GLP-1 Incentive Structures

Employers offering GLP-1 coverage tied to wellness program participation must navigate federal rules governing health-contingent incentives.

6 min read
A magnifying glass held over a smartphone advertisement screen
ExplainerJuly 8, 2025

FTC Scrutiny of Telehealth Weight-Loss Marketing Claims

The Federal Trade Commission has authority over deceptive advertising, and telehealth weight-loss marketing has drawn increasing attention under that authority.

5 min read
A world globe resting on a desk
ExplainerJune 20, 2025

The WHO's Position on GLP-1 Drugs in Global Obesity Policy

The World Health Organization has weighed in on GLP-1 drugs' role in global obesity management, alongside concerns about access equity between wealthy and lower-income countries.

6 min read
An open insurance benefits booklet on a desk
ExplainerJune 2, 2025

What an 'Essential Health Benefit' Designation Would Mean for GLP-1 Coverage

Essential health benefit categories shape what ACA-compliant plans must cover. Here's how that framework interacts with anti-obesity medication coverage debates.

6 min read